ATE359079T1 - Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus - Google Patents

Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus

Info

Publication number
ATE359079T1
ATE359079T1 AT04701830T AT04701830T ATE359079T1 AT E359079 T1 ATE359079 T1 AT E359079T1 AT 04701830 T AT04701830 T AT 04701830T AT 04701830 T AT04701830 T AT 04701830T AT E359079 T1 ATE359079 T1 AT E359079T1
Authority
AT
Austria
Prior art keywords
vomiting
regaging
combination
treating nausea
nausea
Prior art date
Application number
AT04701830T
Other languages
English (en)
Inventor
Steven B Landau
Cheryl L Miller
Karl Bruce Thor
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE359079T1 publication Critical patent/ATE359079T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
AT04701830T 2003-01-13 2004-01-13 Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus ATE359079T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44007603P 2003-01-13 2003-01-13
US49247803P 2003-08-04 2003-08-04

Publications (1)

Publication Number Publication Date
ATE359079T1 true ATE359079T1 (de) 2007-05-15

Family

ID=32718144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701830T ATE359079T1 (de) 2003-01-13 2004-01-13 Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus

Country Status (14)

Country Link
US (3) US20040147510A1 (de)
EP (1) EP1567163B1 (de)
JP (1) JP2006516977A (de)
KR (1) KR20050094843A (de)
AT (1) ATE359079T1 (de)
AU (1) AU2004204827B2 (de)
BR (1) BRPI0406748A (de)
CA (1) CA2512022A1 (de)
DE (1) DE602004005814T2 (de)
ES (1) ES2285407T3 (de)
MX (1) MXPA05007379A (de)
NZ (1) NZ541009A (de)
PL (1) PL378369A1 (de)
WO (1) WO2004062624A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
EP1539172A1 (de) * 2002-08-29 2005-06-15 Arachnova Therapeutics Ltd. Neue therapeutische anwendungen von (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidin
EP2286817A3 (de) * 2003-01-13 2011-06-15 Edusa Pharmaceuticals, Inc Verfahren zur Behandlung von funktionalen Darmerkrankungen
KR20050094843A (ko) * 2003-01-13 2005-09-28 다이노젠 파마세우티컬스, 인코포레이티드 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
ES2290741T3 (es) * 2003-04-04 2008-02-16 Dynogen Pharmaceuticals Inc. Metodo de tratamiento de trastornos del tracto urinario inferior.
WO2005007600A2 (en) * 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
JP2008524252A (ja) * 2004-12-17 2008-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｎｓ障害の処置のためのテトラヒドロイソキノリン化合物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1906951A4 (de) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung von gastrointestinaler hypomotilität und relevanter erkrankungen
WO2007090113A2 (en) * 2006-02-01 2007-08-09 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
WO2007120445A1 (en) * 2006-03-31 2007-10-25 Dynogen Pharmaceuticals, Inc. SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES
WO2007131070A2 (en) * 2006-05-04 2007-11-15 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
WO2008038106A1 (en) * 2006-09-27 2008-04-03 Orchid Chemicals & Pharmaceuticals Limited Venlafaxine extended release formulations
WO2010133663A1 (en) * 2009-05-20 2010-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
CA2905553C (en) 2013-03-14 2021-04-06 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
CN106456611B (zh) * 2014-03-11 2021-07-20 红山生物医药有限公司 用于治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂
RS65379B1 (sr) 2016-04-14 2024-04-30 Sensorion (+)-azasetron za upotrebu u lečenju poremećaja uha
US20230266304A1 (en) * 2020-07-15 2023-08-24 St. Jude Children's Research Hospital, Inc. Obese ferret model and methods of establishing and using the same
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023164132A1 (en) * 2022-02-25 2023-08-31 Neuraxis, Inc. Auricular nerve field stimulation device and methods for using the same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US44450A (en) * 1864-09-27 Improvement in ore-crushers
US254171A (en) * 1882-02-28 Car-axle box
US254172A (en) * 1882-02-28 Half to laweence
US36500A (en) * 1862-09-23 Joseph banks
US203055A (en) * 1878-04-30 Improvement in carpet-stretchers
US107244A (en) * 1870-09-13 Improved manner of treating- cod-liver and castor-oils
US36549A (en) * 1862-09-23 Improvement in caps
US48874A (en) * 1865-07-18 Improved extension door-knobs
US4225407A (en) * 1979-04-04 1980-09-30 The Dow Chemical Company Cathodic electrodeposition of polymers onto a conductive surface
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
EP0201165B1 (de) * 1985-03-14 1994-07-20 Beecham Group Plc Arzneimittel zur Behandlung von Emesis
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
EP0297651B1 (de) * 1987-06-29 1993-11-03 Duphar International Research B.V Anellierte Indolderivate
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
GB9214184D0 (en) 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ATE201021T1 (de) * 1995-07-28 2001-05-15 Dainippon Pharmaceutical Co (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4 diazepin-6-yl)-2-methoxy-6-methylamino-3- pyridincarboxamid, verfahren zu seinerherstellung und dieses enthaltende medizinische zubereitung
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
WO1997029739A2 (en) * 1996-02-15 1997-08-21 Janssen Pharmaceutica N.V. Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
US6235745B1 (en) * 1997-04-18 2001-05-22 Janssen Pharmaceutica N.V. Use of 5HT3, antagonists for promoting intestinal lavage
JPH10298078A (ja) 1997-05-06 1998-11-10 Mitsubishi Chem Corp 抗不安薬
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
EP0901790B1 (de) * 1997-09-16 2001-05-30 Solvay Pharmaceuticals GmbH Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6376550B1 (en) * 1999-02-09 2002-04-23 Asta Medica Ag Pharmaceutical compositions containing tramadol for migraine
JP2002537245A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト ５−ｈｔ３レセプターアンタゴニストの使用
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
GB2355932B (en) * 1999-04-12 2004-01-07 Univ Madras A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
ATE304358T1 (de) * 1999-07-01 2005-09-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von migränekopfschmerzen
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
GB0112494D0 (en) 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
ES2281646T3 (es) 2002-01-18 2007-10-01 Aryx Therapeutics Antagonistas del receptor 5-ht3 y procedimientos de utilizacion.
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
ES2399880T3 (es) 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
CN1668307A (zh) 2002-07-10 2005-09-14 阿瑞科诺沃治疗有限公司 治疗功能性肠紊乱的4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并[2,3－d]嘧啶
EP1539172A1 (de) * 2002-08-29 2005-06-15 Arachnova Therapeutics Ltd. Neue therapeutische anwendungen von (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidin
AU2003290363A1 (en) 2002-12-24 2004-07-22 Amedis Pharmaceuticals Ltd. Therapeutic use of selective noradrenaline reuptake inhibitors
KR20050094843A (ko) * 2003-01-13 2005-09-28 다이노젠 파마세우티컬스, 인코포레이티드 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법
EP2286817A3 (de) * 2003-01-13 2011-06-15 Edusa Pharmaceuticals, Inc Verfahren zur Behandlung von funktionalen Darmerkrankungen

Also Published As

Publication number Publication date
US7094786B2 (en) 2006-08-22
US20040254172A1 (en) 2004-12-16
WO2004062624A3 (en) 2005-04-07
CA2512022A1 (en) 2004-07-29
MXPA05007379A (es) 2006-02-10
EP1567163B1 (de) 2007-04-11
WO2004062624A2 (en) 2004-07-29
DE602004005814D1 (de) 2007-05-24
AU2004204827A1 (en) 2004-07-29
US20040147510A1 (en) 2004-07-29
PL378369A1 (pl) 2006-04-03
EP1567163A2 (de) 2005-08-31
KR20050094843A (ko) 2005-09-28
JP2006516977A (ja) 2006-07-13
DE602004005814T2 (de) 2008-01-10
ES2285407T3 (es) 2007-11-16
NZ541009A (en) 2007-09-28
BRPI0406748A (pt) 2005-12-20
AU2004204827B2 (en) 2006-06-29
EP1567163A4 (de) 2006-01-18
US20040254171A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
AP2006003621A0 (en) Methods for treatment modification and management of pains using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoin-doleline
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
MY151032A (en) Treatment of tnf? related disorders
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
WO2005105094A3 (en) Cancer treatment method
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
TR200200278T2 (tr) Kalsilitik bileşimler
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
PT1469853E (pt) Utilização de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)-tieno[2,3-d]pirimidina para o tratamento da incontinência urinária
CY1108980T1 (el) Χρηση πολυσουλφωμενων κυκλοδεξτρινων για τη θεραπεια της αρθριτιδας
BR0312511A (pt) 4- (2-fluorofenil)-6-metil-2- (1-piperazinil) tieno [2,3-d] pirimidina no tratamento de distúrbio funcional dos intestinos
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
ATE359769T1 (de) Verwendung von 4-(2-fluorophenyl)-6-methyl-2-(1- piperazinyl) thieno (2,3-d)pyrimidin zur schmerzbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties